<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372462</url>
  </required_header>
  <id_info>
    <org_study_id>CP-00-0035</org_study_id>
    <nct_id>NCT01372462</nct_id>
  </id_info>
  <brief_title>Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Pilot Study of the Physiologic Effects of Using the Breathe Technologies Noninvasive Open Ventilation System During Constant Work Rate Exercise in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breathe Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breathe Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study in 15 stable male subjects with severe-to-very severe Chronic Obstructive
      Pulmonary Disease (COPD) to evaluate the effects of short term use of the Breathe
      Technologies noninvasive open ventilation (NIOV) system on respiratory mechanics during
      constant work rate exercise in subjects with severe COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study was a randomized double-blinded crossover design in which subjects completed a series
      of exercises at a constant work rate while using 1) Test noninvasive ventilation (NIOV)
      system powered by compressed air, 2) Test NIOV system powered by 100% oxygen, 3) nasal
      cannula oxygen, 4) nothing (Control). Subjects were assessed during constant work rate
      exercise as reflected by exercise duration, isotime oxygenation (SpO2), and isotime dyspnea
      score (Borg). Exercise sessions took place over 4 visits with each visit lasting
      approximately 5 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test Conditions</measure>
    <time_frame>Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxygen and Nasal Cannula Oxygen.</time_frame>
    <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SpO2 During Constant Workrate Exercise at Isotime</measure>
    <time_frame>Outcome was measured in each of the Study day 1,2, 3 and 4. Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxyg</time_frame>
    <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Dyspnea Score During Constant Workrate Exercise at Isotime</measure>
    <time_frame>Outcome was measured in each Study day 1,2,3 and 4. Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxygen and N</time_frame>
    <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control) at isotime. Borg Dyspnea Score ranges in values from 0 to 10. The lower score represent better outcome.
0 = No breathlessness at all, representing better outcome 10 = Maximum breathlessness, representing worse outcome</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>NIOV - Room air</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIOV - Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Cannula Oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm. Subjects exercise without using supplemental oxygen or NIOV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIOV - Room Air</intervention_name>
    <description>Noninvasive ventilation with device powered by compressed room air.</description>
    <arm_group_label>NIOV - Room air</arm_group_label>
    <other_name>NIOV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIOV - Oxygen</intervention_name>
    <description>Noninvasive ventilation with device powered by compressed medical (100%) oxygen.</description>
    <arm_group_label>NIOV - Oxygen</arm_group_label>
    <other_name>NIOV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal Cannula Oxygen</intervention_name>
    <description>Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.</description>
    <arm_group_label>Nasal Cannula Oxygen</arm_group_label>
    <other_name>Cannula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males, â‰¥ 40 years of age

          -  Diagnosis of severe COPD (GOLD stage III or IV) defined as having a FEV1 &lt; 50% of
             predicted and an FEV1/FVC ratio &lt; 70% of predicted

          -  Ventilatory limitation to exercise, documented by a VE/MVV &gt; 0.85

          -  SpO2 between 80% and 88% during incremental exercise testing on room air

          -  Willingness and ability (after training) to exercise on a cycle ergometer

          -  Willingness and ability to perform all other study related procedures and tasks

          -  Ability to be properly fitted with the Breathe nasal mask

          -  Ability to tolerate and be appropriately titrated on the Breathe ventilator (See
             Appendix E)

          -  Ability to be properly fitted with an exercise mask

          -  Fluency in written and spoken English

          -  Provision of written informed consent

        Exclusion Criteria:

          -  History of acute exacerbation of COPD within 30 days of screening

          -  History of serious epistaxis within 14 days of screening

          -  Requirement of &gt; 5 LPM nasal O2 to maintain an SpO2 &gt; 90% while at rest

          -  History of pneumothorax secondary to lung bullae

          -  History of intolerance to supplemental oxygen

          -  Musculoskeletal or other non-pulmonary impairment that limits exercise tolerance

          -  Inability to achieve an optimal CWR level (4-7 minutes) during Study Visit 1R

          -  Current participation in another interventional study or participation within 14 days
             of screening

          -  Presence of any condition or abnormality that in the opinion of the Principal
             Investigator may compromise the subject's safety or the quality of the study data
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Casaburi, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Biomedical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <results_first_submitted>March 8, 2015</results_first_submitted>
  <results_first_submitted_qc>August 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2016</results_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Ventilator</keyword>
  <keyword>Constant work rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>All subjects completed all 4 visit days in which they were randomized to receive which treatment to receive first: 1) NIOV - Oxygen, 2) NIOV - Room Air, 3) Oxygen Nasal Cannula, 4) No treatment.
Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxygen and Nasal Cannula Oxygen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>NIOV - Room Air</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>NIOV - Oxygen</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Oxygen Nasal Cannula</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>No Treatment Control</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The primary endpoint is difference in endurance between cannula oxygen and NIOV+O2. Assuming 153 sec clinically important difference, 183 sec SD of increase and Î±=0.05, a sample size of 15 yields 85% power.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Group</title>
          <description>Crossover design. Subject were randomized to complete all 4 study arms: 1) NIOV - Oxygen, 2) NIOV - Room Air, 3) Oxygen Nasal Cannula, 4) No treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Only male subjects were recruited due to need for placement of sensors on an exposed chest area.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test Conditions</title>
        <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).</description>
        <time_frame>Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxygen and Nasal Cannula Oxygen.</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>NIOV - Room Air</title>
            <description>Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
NIOV - Room Air: Noninvasive ventilation with device powered by compressed room air.</description>
          </group>
          <group group_id="O2">
            <title>NIOV - Oxygen</title>
            <description>Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
NIOV - Oxygen: Noninvasive ventilation with device powered by compressed medical (100%) oxygen.</description>
          </group>
          <group group_id="O3">
            <title>Nasal Cannula Oxygen</title>
            <description>Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
Nasal Cannula Oxygen: Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>Control arm. Subjects exercise without using supplemental oxygen or NIOV.</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test Conditions</title>
          <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).</description>
          <population>Per protocol analysis</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="4.1"/>
                    <measurement group_id="O2" value="17.5" spread="5.7"/>
                    <measurement group_id="O3" value="11.4" spread="6.8"/>
                    <measurement group_id="O4" value="5.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint was difference in endurance between nasal cannula oxygen and NIOV+O2. Assuming 153 sec clinically important difference, 183 sec SD, and Î±=0.05, a sample size of 15 yielded 85% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Newman-Keuls multiple comparisons test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SpO2 During Constant Workrate Exercise at Isotime</title>
        <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).</description>
        <time_frame>Outcome was measured in each of the Study day 1,2, 3 and 4. Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxyg</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>NIOV - Room Air</title>
            <description>Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
NIOV - Room Air: Noninvasive ventilation with device powered by compressed room air.</description>
          </group>
          <group group_id="O2">
            <title>NIOV - Oxygen</title>
            <description>Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
NIOV - Oxygen: Noninvasive ventilation with device powered by compressed medical (100%) oxygen.</description>
          </group>
          <group group_id="O3">
            <title>Nasal Cannula Oxygen</title>
            <description>Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
Nasal Cannula Oxygen: Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>Control arm. Subjects exercise without using supplemental oxygen or NIOV.</description>
          </group>
        </group_list>
        <measure>
          <title>SpO2 During Constant Workrate Exercise at Isotime</title>
          <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).</description>
          <population>Per Protocol</population>
          <units>percentage of oxyHb saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" spread="3.8"/>
                    <measurement group_id="O2" value="98.5" spread="1.0"/>
                    <measurement group_id="O3" value="92.7" spread="3.9"/>
                    <measurement group_id="O4" value="88.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-way, repeated-measures ANOVA and Newman-Keuls multiple comparisons test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Newman-Keuls multiple comparisons test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg Dyspnea Score During Constant Workrate Exercise at Isotime</title>
        <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control) at isotime. Borg Dyspnea Score ranges in values from 0 to 10. The lower score represent better outcome.
0 = No breathlessness at all, representing better outcome 10 = Maximum breathlessness, representing worse outcome</description>
        <time_frame>Outcome was measured in each Study day 1,2,3 and 4. Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxygen and N</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>NIOV - Room Air</title>
            <description>Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
NIOV - Room Air: Noninvasive ventilation with device powered by compressed room air.</description>
          </group>
          <group group_id="O2">
            <title>NIOV - Oxygen</title>
            <description>Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
NIOV - Oxygen: Noninvasive ventilation with device powered by compressed medical (100%) oxygen.</description>
          </group>
          <group group_id="O3">
            <title>Nasal Cannula Oxygen</title>
            <description>Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
Nasal Cannula Oxygen: Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>Control arm. Subjects exercise without using supplemental oxygen or NIOV.</description>
          </group>
        </group_list>
        <measure>
          <title>Borg Dyspnea Score During Constant Workrate Exercise at Isotime</title>
          <description>Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control) at isotime. Borg Dyspnea Score ranges in values from 0 to 10. The lower score represent better outcome.
0 = No breathlessness at all, representing better outcome 10 = Maximum breathlessness, representing worse outcome</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.8"/>
                    <measurement group_id="O2" value="1.8" spread="1.3"/>
                    <measurement group_id="O3" value="2.5" spread="1.7"/>
                    <measurement group_id="O4" value="4.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Per protocol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>One-way, repeated-measures ANOVA and Newman-Keuls multiple comparisons tests</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Newman-Keuls multiple comparisons tests</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Continuously for up to 8 hours on study days in which exercise testing was conducted</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NIOV - Room Air</title>
          <description>Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
NIOV - Room Air: Noninvasive ventilation with device powered by compressed room air.</description>
        </group>
        <group group_id="E2">
          <title>NIOV - Oxygen</title>
          <description>Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
NIOV - Oxygen: Noninvasive ventilation with device powered by compressed medical (100%) oxygen.</description>
        </group>
        <group group_id="E3">
          <title>Nasal Cannula Oxygen</title>
          <description>Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
Nasal Cannula Oxygen: Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.</description>
        </group>
        <group group_id="E4">
          <title>No Treatment</title>
          <description>Control arm. Subjects exercise without using supplemental oxygen or NIOV.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard J. Morishige, MS, RRT</name_or_title>
      <organization>Clinical Research Consulting</organization>
      <phone>510-606-0375</phone>
      <email>rjmorishige@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

